These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24055776)

  • 1. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
    Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
    Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.
    Chien YH; Bodamer OA; Chiang SC; Mascher H; Hung C; Hwu WL
    J Inherit Metab Dis; 2013 Sep; 36(5):881-5. PubMed ID: 23109060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.
    Rombach SM; Dekker N; Bouwman MG; Linthorst GE; Zwinderman AH; Wijburg FA; Kuiper S; Vd Bergh Weerman MA; Groener JE; Poorthuis BJ; Hollak CE; Aerts JM
    Biochim Biophys Acta; 2010 Sep; 1802(9):741-8. PubMed ID: 20471476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
    Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
    J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.
    Krüger R; Tholey A; Jakoby T; Vogelsberger R; Mönnikes R; Rossmann H; Beck M; Lackner KJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():128-35. PubMed ID: 22138589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
    van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
    Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic progression to clinical phenotype in classic Fabry disease.
    Spada M; Kasper D; Pagliardini V; Biamino E; Giachero S; Porta F
    Ital J Pediatr; 2017 Jan; 43(1):1. PubMed ID: 28049500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.
    Auray-Blais C; Lavoie P; Boutin M; Ntwari A; Hsu TR; Huang CK; Niu DM
    Clin Chim Acta; 2017 Mar; 466():185-193. PubMed ID: 28108302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
    Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
    Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LysoGb3 quantification facilitates phenotypic categorization of Fabry disease patients: Insights gained by a novel MS/MS method.
    Kuchar L; Berna L; Poupetova H; Ledvinova J; Ruzicka P; Dostalova G; Reichmannova S; Asfaw B; Linhart A; Sikora J
    Clin Chim Acta; 2024 Jul; 561():119824. PubMed ID: 38906396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.
    Nowak A; Mechtler TP; Desnick RJ; Kasper DC
    Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
    Arends M; Wijburg FA; Wanner C; Vaz FM; van Kuilenburg ABP; Hughes DA; Biegstraaten M; Mehta A; Hollak CEM; Langeveld M
    Mol Genet Metab; 2017 Jun; 121(2):157-161. PubMed ID: 28495078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
    Sueoka H; Ichihara J; Tsukimura T; Togawa T; Sakuraba H
    PLoS One; 2015; 10(5):e0127048. PubMed ID: 25965380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).
    Lin HY; Huang CH; Yu HC; Chong KW; Hsu JH; Lee PC; Cheng KH; Chiang CC; Ho HJ; Lin SP; Chen SJ; Lin PK; Niu DM
    J Inherit Metab Dis; 2010 Oct; 33(5):619-24. PubMed ID: 20821055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.
    Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM
    J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
    Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
    Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of lyso-globotriaosylsphingosine in dried blood spots.
    Johnson B; Mascher H; Mascher D; Legnini E; Hung CY; Dajnoki A; Chien YH; Maródi L; Hwu WL; Bodamer OA
    Ann Lab Med; 2013 Jul; 33(4):274-8. PubMed ID: 23826564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Globotriaosylsphingosine (Lyso-Gb
    Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
    J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.